Arcturus Therapeutics Holdings Inc. Stock Research

Market Summary

USD15.85+0.15

Delayedas of 27 Mar 2023, 02:00 pm

0.96%

ARCT Stock Price

ARCT RSI Chart

ARCT Valuation

Market Cap

415.9M

Price/Earnings (Trailing)

-2.84

Price/Sales (Trailing)

8.08

Price/Free Cashflow

-2.37

ARCT Price/Sales (Trailing)

ARCT Profitability

Return on Equity

-100.68%

Return on Assets

-49.95%

Free Cashflow Yield

-42.27%

ARCT Fundamentals

ARCT Revenue

Revenue (TTM)

51.5M

Revenue Y/Y

448.58%

Revenue Q/Q

-50.66%

ARCT Earnings

Earnings (TTM)

-146.7M

Earnings Y/Y

34.79%

Earnings Q/Q

-63.55%

Price Action

52 Week Range

11.7031.41

(Low)(High)

Last 7 days

-1.1%

Last 30 days

-10.7%

Last 90 days

-9.0%

Trailing 12 Months

-44.1%

ARCT Financial Health

Current Ratio

3.25

Debt/Equity

0.09

Debt/Cashflow

-12.84

ARCT Investor Care

Shares Dilution (1Y)

0.58%

Diluted EPS (TTM)

-5.56

Peers (Alternatives to Arcturus Therapeutics Holdings)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
BGNE	298.0B	1.4B	-3.25%	8.54%	-148.7	210.43	20.37%	-37.45%
ABBV	279.9B	58.1B	4.88%	1.38%	23.64	4.82	3.30%	2.55%
REGN	87.7B	12.2B	9.61%	20.63%	20.21	7.2	-24.26%	-46.28%
VRTX	80.8B	8.9B	6.80%	24.91%	24.32	9.05	17.91%	41.84%
ALNY	23.5B	1.0B	-5.53%	16.05%	-20.81	22.69	22.88%	-32.64%
SRPT	11.5B	933.0M	2.93%	61.85%	-16.28	12.27	32.93%	-67.99%
UTHR	10.1B	1.9B	-9.77%	22.96%	13.92	5.23	14.88%	52.86%
MID-CAP
MDGL	4.2B	504.0K	-19.59%	144.55%	-14.38	2.5K	-66.53%	-22.12%
RARE	2.6B	363.3M	-18.37%	-45.49%	-3.74	7.28	3.39%	-55.81%
BPMC	2.6B	204.0M	1.49%	-34.21%	-4.68	12.78	13.30%	13.44%
MRTX	2.3B	12.4M	-15.06%	-52.42%	-3.05	181.9	-	-27.34%
SMALL-CAP
CPRX	1.7B	214.2M	4.81%	93.98%	20.42	7.92	52.10%	110.42%
MGNX	412.2M	151.9M	1.98%	-27.23%	-3.44	2.71	96.19%	40.75%
CRBP	28.6M	-	145.52%	1270.00%	-0.67	19.11	-77.61%	7.22%
CYTK	3.1M	94.6M	-20.08%	-11.44%	-0.01	0.03	34.30%	-80.65%

Financials for Arcturus Therapeutics Holdings

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	26.9%	51,500,000	40,568,000	15,476,000	12,359,000	8,803,000
Operating Expenses	-3.0%	198,420,000	204,502,000	211,041,000	215,211,000	205,092,000
S&GA Expenses	3.8%	45,017,000	43,389,000	42,438,000	41,451,000	39,679,000
R&D Expenses	-4.8%	153,403,000	161,113,000	168,603,000	173,760,000	165,413,000
EBITDA	-	-19,845,000	-	-	-	-
EBITDA Margin	-	-2.25	-	-	-	-
EBT Margin	-	-2.47	-	-	-	-
Interest Expenses	8.2%	755,000	698,000	684,000	684,000	1,092,000
Net Income	11.4%	-146,661,000	-165,479,000	-198,497,000	-203,674,000	-196,115,000
Net Income Margin	30.2%	-2.85	-4.08	-12.83	-	-
Free Cahsflow	-17.5%	-175,800,000	-149,627,000	-146,531,000	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Assets	-12.9%	294	337	342	393	435
Current Assets	-15.4%	247	292	327	379	421
Cash Equivalents	-16.2%	238	283	320	370	414
Net PPE	26.8%	11.00	9.00	8.00	6.00	5.00
Liabilities	-11.0%	148	166	157	165	175
Current Liabilities	-18.2%	76.00	93.00	107	100	118
Long Term Debt	-13.1%	13.00	15.00	15.00	15.00	15.00
LT Debt, Current	2.5%	28.00	27.00	24.00	22.00	-
LT Debt, Non Current	-10.4%	32.00	36.00	39.00	41.00	42.00
Shareholder's Equity	-14.7%	146	171	185	228	259
Retained Earnings	-8.4%	-455	-420	-398	-347	-308
Additional Paid-In Capital	1.7%	601	591	583	576	568
Accumulated Depreciation	8.7%	5.00	5.00	4.00	4.00	4.00
Shares Outstanding	0.2%	26.00	26.00	26.00	26.00	26.00

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3
Cashflow From Operations	-17.8%	-170,763	-145,010	-141,132	-135,043	-99,178
Share Based Compensation	8.8%	31,599	29,033	29,299	28,915	24,223
Cashflow From Investing	-9.1%	-5,037	-4,617	-5,399	-3,406	-2,985
Cashflow From Financing	-126.2%	-397	1,515	1,340	48,016	210,987

Risks for ARCT

What is the probability of a big loss on ARCT?

100%

Probability that Arcturus Therapeutics Holdings stock will be more than 20% underwater in next one year

100%

Probability that Arcturus Therapeutics Holdings stock will be more than 30% underwater in next one year.

92.3%

Probability that Arcturus Therapeutics Holdings stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARCT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcturus Therapeutics Holdings was unfortunately bought at previous high price.

Drawdowns

Returns for ARCT

Cumulative Returns on ARCT

-7.3%

7-Year Cumulative Returns

22.2%

5-Year Cumulative Returns

0.8%

3-Year Cumulative Returns

What are the long-term rolling returns for ARCT?

FIve years rolling returns for Arcturus Therapeutics Holdings.

Annualized Returns

Which funds bought or sold ARCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-02-21	MACQUARIE GROUP LTD	sold off	-	-4,000	-	-%
2023-02-15	JANE STREET GROUP, LLC	added	174	986,401	1,447,400	-%
2023-02-15	Point72 Middle East FZE	new	-	79,254	79,254	-%
2023-02-15	UNITED CAPITAL FINANCIAL ADVISERS, LLC	sold off	-100	-370,000	-	-%
2023-02-15	Financial Gravity Asset Management, Inc.	new	-	32.00	32.00	-%
2023-02-15	Metropolitan Life Insurance Co/NY	unchanged	-	2,642	23,642	-%
2023-02-15	MetLife Investment Management, LLC	unchanged	-	26,066	209,066	-%
2023-02-15	SALEM INVESTMENT COUNSELORS INC	unchanged	-	696	1,696	-%
2023-02-15	LAZARD ASSET MANAGEMENT LLC	reduced	-7.42	7,000	140,000	-%
2023-02-15	ALLIANCEBERNSTEIN L.P.	unchanged	-	48,688	386,688	-%

Latest Funds Activity

Are funds buying ARCT calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ARCT

No. of Funds

Arcturus Therapeutics Holdings News

Schedule 13G FIlings of Arcturus Therapeutics Holdings

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 09, 2023	vanguard group inc	5.46%	1,450,425	SC 13G
Feb 08, 2023	state street corp	8.50%	2,257,846	SC 13G/A
Feb 03, 2023	sumitomo mitsui trust holdings, inc.	5.45%	1,449,060	SC 13G/A
Feb 01, 2023	federated hermes, inc.	16.00%	4,239,554	SC 13G/A
Jan 31, 2023	blackrock inc.	7.1%	1,884,885	SC 13G/A
Apr 11, 2022	state street corp	12.20%	3,217,957	SC 13G/A
Feb 14, 2022	nikko asset management americas, inc.	5.15%	1,357,472	SC 13G
Feb 14, 2022	federated hermes, inc.	14.02%	3,694,929	SC 13G
Feb 14, 2022	price t rowe associates inc /md/	0.0%	15,039	SC 13G/A
Feb 11, 2022	state street corp	7.80%	2,056,074	SC 13G

ARCT Fair Value

Arcturus Therapeutics Holdings fair value in different scenarios

The table shows the Fair Value estimates for Arcturus Therapeutics Holdings for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.

Fair Value	Very Pessimistic	Pessimistic	Base Case	Optimistic	Very Optimistic
Very Low Inflation	1.35 -91.48%	1.54 -90.28%	1.96 -87.63%	5.02 -68.33%	8.99 -43.28%
Current Inflation	1.34 -91.55%	1.51 -90.47%	1.89 -88.08%	4.54 -71.36%	7.95 -49.84%
Very High Inflation	1.33 -91.61%	1.48 -90.66%	1.80 -88.64%	3.98 -74.89%	6.75 -57.41%

Historical Arcturus Therapeutics Holdings Fair Value Estimates

Very Pessimistic Case

Pessimistic Case

Fair Value

Optimistic Case

Very Optimistic Case

Closing Stock Price

Recent SEC filings of Arcturus Therapeutics Holdings

View All Filings

Date Filed	Form Type	Document
Mar 17, 2023	8-K	Current Report
Mar 08, 2023	4	Insider Trading
Feb 10, 2023	SC 13G/A	Major Ownership Report
Feb 10, 2023	SC 13G/A	Major Ownership Report
Feb 09, 2023	SC 13G	Major Ownership Report
Feb 08, 2023	SC 13G/A	Major Ownership Report
Feb 03, 2023	SC 13G/A	Major Ownership Report
Feb 01, 2023	SC 13G/A	Major Ownership Report
Jan 31, 2023	SC 13G/A	Major Ownership Report
Dec 30, 2022	EFFECT	EFFECT

Latest Insider Trading transactions for ARCT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-03-06	Chivukula Pad	sold	-80,350	16.07	-5,000	chief scientific officer & coo
2022-12-15	Marquet Magda	bought	39,996	18.00	2,222	-
2022-11-23	Payne Joseph E	bought	82,550	16.51	5,000	president and ceo
2022-08-15	SASSINE ANDY	acquired	19,672	18.4195	1,068	chief financial officer
2022-01-04	Chivukula Pad	sold	-324,000	40.00	-8,100	chief scientific officer & coo
2021-12-16	Chivukula Pad	sold	-145,328	40.0021	-3,633	chief scientific officer & coo
2021-12-08	Chivukula Pad	sold	-254,680	40.00	-6,367	chief scientific officer & coo
2021-11-01	Chivukula Pad	sold	-444,100	44.41	-10,000	chief scientific officer & coo
2021-10-01	Chivukula Pad	sold	-443,600	44.36	-10,000	chief scientific officer & coo
2021-09-01	Chivukula Pad	sold	-558,600	55.86	-10,000	chief scientific officer & coo

About Arcturus Therapeutics Holdings

ARCT Income Statement

2022-09-30

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Revenue	$ 13,369	$ 2,437	$ 45,706	$ 6,565
Operating expenses:
Research and development, net	37,688	45,398	120,770	141,127
General and administrative	12,488	10,860	34,211	30,645
Total operating expenses	50,176	56,258	154,981	171,772
Loss from operations	(36,807)	(53,821)	(109,275)	(165,207)
Gain (loss) from equity-method investment		(250)	(515)	670
Gain from foreign currency	1,862	506	3,237	923
Finance expense, net	(321)	(519)	(1,445)	(1,397)
Net loss	$ (35,266)	$ (54,084)	$ (107,998)	$ (165,011)
Net loss per share, basic	$ (1.33)	$ (2.05)	$ (4.09)	$ (6.27)
Net loss per share, diluted	$ (1.33)	$ (2.05)	$ (4.09)	$ (6.27)
Weighted-average shares outstanding, basic	26,467	26,338	26,423	26,302
Weighted-average shares outstanding, diluted	26,467	26,338	26,423	26,302
Comprehensive loss:
Net loss	$ (35,266)	$ (54,084)	$ (107,998)	$ (165,011)
Comprehensive loss	$ (35,266)	$ (54,084)	$ (107,998)	$ (165,011)

ARCT Balance Sheet

2022-09-30

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 237,676	$ 370,492
Accounts receivable	2,044	3,367
Prepaid expenses and other current assets	6,960	5,102
Total current assets	246,680	378,961
Property and equipment, net	11,347	5,643
Operating lease right-of-use asset, net	33,519	5,618
Equity-method investment		515
Non-current restricted cash	2,081	2,077
Total assets	293,627	392,814
Current liabilities:
Accounts payable	17,962	10,058
Accrued liabilities	25,529	23,523
Current portion of long-term debt	27,702	22,474
Deferred revenue	4,656	43,482
Total current liabilities	75,849	99,537
Deferred revenue, net of current portion	5,179	19,931
Long-term debt, net of current portion	32,038	40,633
Operating lease liability, net of current portion	31,218	4,502
Other non-current liabilities	3,676
Total liabilities	147,960	164,603
Stockholders’ equity
Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,492 at September 30, 2022 and 26,372 at December 31, 2021	26	26
Additional paid-in capital	601,129	575,675
Accumulated deficit	(455,488)	(347,490)
Total stockholders’ equity	145,667	228,211
Total liabilities and stockholders’ equity	$ 293,627	$ 392,814